https://www.selleckchem.com/products/OSI-906.html
Phosphodiesterase 10 (PDE1 inhibitors have received much attention as promising therapeutic agents for central nervous system (CNS) disorders such as schizophrenia and Huntington's disease. Recently, a hit compound 1 with a novel chromone scaffold has shown moderate inhibitory activity against PDE10A (IC50 = 500 nM). Hit-to-lead optimization has resulted in compound 3e with an improved inhibitory activity (IC50 = 6.5 nM), remarkable selectivity (95-fold over other PDEs), and good metabolic stability (RLM t1/2 = 105 min) by using a
Like
Comment
Share
